Halena R. VanDeusen
Research Subjects
Research Interests
Halena R. VanDeusen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Anjali V. Sheahan
7 shared publicationsAshley Petersen
7 shared publicationsColm Morrissey
7 shared publications- Eva Corey
Department of Urology, University of Washington, Seattle, WA 98195, USA
7 shared publications Ilsa Coleman
7 shared publications- John K. Lee
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
7 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines
- Open Access
- 27 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (8) , 1176-1188
Targeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative. Implications: Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.
- 27 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (8) , 1176-1188
Open AccessTargeting RET Kinase in Neuroendocrine Prostate Cancer
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative. Implications: Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.